NewsBenzingaLifecore Biomedical: utile per azione (EPS) del terzo trimestre pari a $(1,08), sotto le stime di $(0,28); ricavi a 25,322 milioni di dollari, sotto le stime di 26,699 milioni di dollari. Lifecore Biomedical: utile per azione (EPS) del terzo trimestre pari a $(1,08), sotto le stime di $(0,28); ricavi a 25,322 milioni di dollari, sotto le stime di 26,699 milioni di dollari. Benzinga 2026.11.04 12:24 (GMT+0) Open on Benzinga Other news Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $120 Autolus Therapeutics To Present Clinical Update Abstracts At American Society of Hematology Meeting, December 12-15 Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $22 Magic Empire Global Secures $100M Facility From Anyu International To Finance Its Timber Supply Chain Trading Operations Wedbush Maintains Outperform on Denali Therapeutics, Raises Price Target to $24 Conference call: Stanley Black & Decker Sees FY 2026 Sales expected to be flat YoY
Autolus Therapeutics To Present Clinical Update Abstracts At American Society of Hematology Meeting, December 12-15
Magic Empire Global Secures $100M Facility From Anyu International To Finance Its Timber Supply Chain Trading Operations
